M

Madrigal Pharmaceuticals
D

MDGL

267.27
USD
-5.51
(-2.02%)
مغلق
حجم التداول
15,815
الربح لكل سهم
-13
العائد الربحي
-
P/E
-15
حجم السوق
5,934,271,180
أصول ذات صلة
E
EXEL
-0.480
(-1.12%)
42.380 USD
INSM
INSM
1.360
(2.06%)
67.530 USD
K
KPTI
-0.06000
(-1.29%)
4.58000 USD
المزيد
الأخبار المقالات

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.